Elotuzumab 是一种针对 SLAMF7 受体的单克隆抗体。当作为复发或难治性多发性骨髓瘤 (RRMM) 的单一药物给予时，Elotuzumab 没有显着的抗骨髓瘤活性。与其他抗骨髓瘤药物联合使用时，Elotuzumab 可改善反应和结果。
| Cas No. | 915296-00-3 |
| 别名 | 埃罗妥珠单抗,Empliciti; HuLuc 63; PDL 063; BMS 901608 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1]. [1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195. |
